MedTrace Logo

Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®

NCT00488371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2007-12-20

No results posted yet for this study

Summary

Primary Objective:

To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution

Secondary Objective:

To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic resistant pneumococci and serotype distribution.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

Pneumococcal Conjugated Vaccine (Prevnar®)

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

  • Trial Manager · For Taiwan, [email protected]

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Completion
2007-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00488371 on ClinicalTrials.gov